APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

Targeting CD40 with agonist antibodies is a promising approach to cancer immunotherapy. CD40 acts as a master regulator of immunity by mobilizing multiple arms of the immune system to initiate highly effective CD8 + T-cell-mediated responses against foreign pathogens and tumors. The clinical develop...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Immunol Immunother
Main Authors: Filbert, Erin L., Björck, Pia K., Srivastava, Minu K., Bahjat, Frances R., Yang, Xiaodong
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2021
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8195934/
https://ncbi.nlm.nih.gov/pubmed/33392713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02814-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki